ReviewCancers2021
Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Efficacy and Safety of Radiotherapy and Systemic Treatments in Adrenocortical Carcinoma: Systematic Review and Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2025Pooled it
- In Silico Hazard Assessment of Ototoxicants Through Machine Learning and Computational Systems Biology.Toxics · 2026Article
- Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study.Endocrine oncology (Bristol, England) · 2026Article
- Real-world safety profile of mitotane in adrenocortical carcinoma: a retrospective cross-sectional study integrating pharmacovigilance and interpretable machine learning.Frontiers in endocrinology · 2026Article
- Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma.Endocrine oncology (Bristol, England) · 2026Article
- Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell Model.Current oncology (Toronto, Ont.) · 2025Article
- Update on diagnostic and therapeutic challenges of central hypothyroidism among childhood cancer survivors.Journal of endocrinological investigation · 2025Review
- Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study.Children (Basel, Switzerland) · 2025Article
- Oncological Management of Adrenocortical Carcinoma: An Update and Critical Review.Oncology and therapy · 2025Review
- A review of mitotane in the management of adrenocortical cancer.The oncologist · 2024Review
- Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma - case series and literature review.Pediatric endocrinology, diabetes, and metabolism · 2024Review
- Safe long-term therapy of Cushing's syndrome over 37 years with mitotane.Frontiers in endocrinology · 2024Review
- Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy.Frontiers in endocrinology · 2023Article
- Case Report: Adrenocortical carcinoma in children-symptoms, diagnosis, and treatment.Frontiers in endocrinology · 2023Review
- Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.Frontiers in oncology · 2023Article
- System analysis identifies UBE2C as a novel oncogene target for adrenocortical carcinoma.PloS one · 2023Article
- Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.Frontiers in endocrinology · 2023Article
- Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the pivotal role of mitotane in adrenocortical carcinoma (ACC) management, data on the endocrine toxicities of this treatment are lacking. The aim of this systematic review is to collect the available evidence on the side effects of mitotane on the endocrine and metabolic systems in both children and adults affected by adrenal carcinoma. Sixteen articles on 493 patients were included. Among the adrenal insufficiency, which is an expected side effect of mitotane, 24.5% of patients increased glucocorticoid replacement therapy. Mineralocorticoid insufficiency usually occurred late in treatment in 36.8% of patients. Thyroid dysfunction is characterized by a decrease in FT4, which occurs within 3-6 months of treatment in 45.4% of patients, while TSH seems to not be a reliable marker. Dyslipidemia is characterized by an increase in both LDL-c and HDL-c (54.2%). Few studies have found evidence of hypertriglyceridemia. In males, gynecomastia and hypogonadism can occur after 3-6 months of treatment (38.4% and 35.6%, respectively), while in pre-menopausal women, mitotane can cause ovarian cysts and, less frequently, menstrual disorders. Most of these side effects appear to be reversible after mitotane discontinuation. We finally suggest an algorithm that could guide metabolic and endocrine safety assessments in patients treated with mitotane for ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.